MGMT and glioblastoma: The aim of the present phase II study was therefore to evaluate the effect of a prolonged TMZ schedule of 75 mg/m2/daily for 21 days every 28 days in relation to progression-free survival at 6 months (PFS-6), response, toxicity and any correlation with MGMT gene promoter methylation status, in patients with recurrent or progressive GBM.